Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR, Borggrefe M, Dorian P, Camm AJ; Azimilide Trials Investigators. Pratt CM, et al. Among authors: brum jm. J Am Coll Cardiol. 2006 Aug 1;48(3):471-7. doi: 10.1016/j.jacc.2006.04.075. Epub 2006 Jul 12. J Am Coll Cardiol. 2006. PMID: 16875971 Free article.
The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ; ALIVE Investigators. Pratt CM, et al. Among authors: brum jm. J Am Coll Cardiol. 2004 Apr 7;43(7):1211-6. doi: 10.1016/j.jacc.2003.10.057. J Am Coll Cardiol. 2004. PMID: 15063432 Free article. Clinical Trial.
Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator.
Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH; SHIELD Investigators. Pratt CM, et al. Among authors: brum jm. Am J Cardiol. 2005 Jan 15;95(2):274-6. doi: 10.1016/j.amjcard.2004.08.096. Am J Cardiol. 2005. PMID: 15642569
Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P; Shock Inhibition Evaluation with Azimilide Investigators. Dorian P, et al. Among authors: brum jm. J Am Coll Cardiol. 2008 Sep 23;52(13):1076-83. doi: 10.1016/j.jacc.2008.05.055. J Am Coll Cardiol. 2008. PMID: 18848141 Free article. Clinical Trial.
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Dorian P, et al. Among authors: brum jm. Circulation. 2004 Dec 14;110(24):3646-54. doi: 10.1161/01.CIR.0000149240.98971.A8. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533855 Clinical Trial.
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.
Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P; SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators. Hohnloser SH, et al. Among authors: brum jm. Eur Heart J. 2006 Dec;27(24):3027-32. doi: 10.1093/eurheartj/ehl276. Epub 2006 Oct 18. Eur Heart J. 2006. PMID: 17050586 Clinical Trial.
Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM; AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Camm AJ, et al. Among authors: brum jm. Circulation. 2004 Mar 2;109(8):990-6. doi: 10.1161/01.CIR.0000117090.01718.2A. Epub 2004 Feb 16. Circulation. 2004. PMID: 14967728 Clinical Trial.
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Hudson MP, et al. J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. doi: 10.1016/j.jacc.2006.02.055. Epub 2006 Jun 21. J Am Coll Cardiol. 2006. PMID: 16814643 Free article. Clinical Trial.
63 results